 Martin McCarter
Concepts (754)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 44 | 2023 | 631 | 6.820 |
Why?
| | Esophageal Neoplasms | 25 | 2023 | 273 | 5.290 |
Why?
| | Skin Neoplasms | 29 | 2023 | 762 | 3.680 |
Why?
| | Esophagectomy | 18 | 2023 | 111 | 3.310 |
Why?
| | Adenocarcinoma | 23 | 2023 | 801 | 3.000 |
Why?
| | Sentinel Lymph Node Biopsy | 21 | 2022 | 100 | 2.490 |
Why?
| | Myeloid-Derived Suppressor Cells | 4 | 2023 | 58 | 2.450 |
Why?
| | Gastrointestinal Stromal Tumors | 10 | 2022 | 43 | 2.340 |
Why?
| | Neoadjuvant Therapy | 12 | 2023 | 305 | 1.830 |
Why?
| | Sentinel Lymph Node | 9 | 2022 | 37 | 1.800 |
Why?
| | Dendritic Cells | 13 | 2019 | 436 | 1.770 |
Why?
| | T-Lymphocytes, Regulatory | 11 | 2022 | 343 | 1.760 |
Why?
| | Pancreatic Neoplasms | 14 | 2021 | 733 | 1.750 |
Why?
| | Neoplasm Recurrence, Local | 18 | 2019 | 863 | 1.650 |
Why?
| | Tumor Escape | 4 | 2017 | 36 | 1.300 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 1361 | 1.270 |
Why?
| | Lymphatic Metastasis | 18 | 2023 | 281 | 1.260 |
Why?
| | Hyperthermia, Induced | 4 | 2020 | 65 | 1.250 |
Why?
| | Neoplasm Staging | 29 | 2023 | 1180 | 1.190 |
Why?
| | Middle Aged | 90 | 2022 | 26806 | 1.110 |
Why?
| | Hyperglycemia | 3 | 2020 | 292 | 1.100 |
Why?
| | Humans | 186 | 2024 | 114935 | 1.090 |
Why?
| | Aged | 76 | 2021 | 19122 | 1.080 |
Why?
| | HIV-1 | 16 | 2022 | 767 | 1.060 |
Why?
| | Retrospective Studies | 49 | 2023 | 12544 | 1.050 |
Why?
| | Lymph Nodes | 14 | 2023 | 425 | 1.030 |
Why?
| | Neoplasms | 10 | 2024 | 2106 | 1.020 |
Why?
| | HIV Infections | 20 | 2022 | 2469 | 1.010 |
Why?
| | CD4-Positive T-Lymphocytes | 13 | 2021 | 966 | 1.000 |
Why?
| | Postoperative Complications | 19 | 2023 | 2133 | 1.000 |
Why?
| | Rectal Neoplasms | 7 | 2023 | 121 | 0.980 |
Why?
| | Intestinal Mucosa | 10 | 2021 | 530 | 0.930 |
Why?
| | Peritoneal Neoplasms | 3 | 2020 | 54 | 0.890 |
Why?
| | Laparoscopy | 7 | 2023 | 389 | 0.840 |
Why?
| | Male | 101 | 2022 | 55663 | 0.830 |
Why?
| | Pancreaticoduodenectomy | 7 | 2021 | 133 | 0.830 |
Why?
| | Lymph Node Excision | 8 | 2022 | 142 | 0.830 |
Why?
| | Cytoreduction Surgical Procedures | 4 | 2020 | 38 | 0.820 |
Why?
| | Female | 110 | 2022 | 59580 | 0.810 |
Why?
| | Tretinoin | 3 | 2023 | 125 | 0.810 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 94 | 0.790 |
Why?
| | Lymphocyte Activation | 11 | 2018 | 1045 | 0.770 |
Why?
| | Sarcoma | 5 | 2022 | 138 | 0.770 |
Why?
| | Stomach Neoplasms | 2 | 2019 | 65 | 0.770 |
Why?
| | Radiosurgery | 4 | 2020 | 303 | 0.750 |
Why?
| | Pelvic Exenteration | 4 | 2019 | 11 | 0.740 |
Why?
| | T-Lymphocytes | 6 | 2018 | 1749 | 0.740 |
Why?
| | Proto-Oncogene Proteins c-kit | 5 | 2022 | 63 | 0.740 |
Why?
| | Survival Analysis | 16 | 2022 | 1220 | 0.700 |
Why?
| | Adult | 60 | 2020 | 30608 | 0.690 |
Why?
| | Splenectomy | 1 | 2020 | 51 | 0.690 |
Why?
| | Prognosis | 22 | 2022 | 3344 | 0.680 |
Why?
| | Gastrointestinal Microbiome | 8 | 2021 | 502 | 0.670 |
Why?
| | Piperazines | 5 | 2014 | 313 | 0.670 |
Why?
| | Pancreatic Cyst | 2 | 2017 | 48 | 0.670 |
Why?
| | Ipilimumab | 2 | 2019 | 29 | 0.660 |
Why?
| | Spleen | 6 | 2017 | 485 | 0.660 |
Why?
| | Anastomotic Leak | 3 | 2023 | 27 | 0.650 |
Why?
| | Myeloid Cells | 3 | 2020 | 128 | 0.650 |
Why?
| | Pyrimidines | 5 | 2014 | 378 | 0.640 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2018 | 125 | 0.630 |
Why?
| | Granulocytes | 2 | 2017 | 78 | 0.630 |
Why?
| | Colorectal Neoplasms | 5 | 2017 | 621 | 0.610 |
Why?
| | Aged, 80 and over | 27 | 2020 | 6364 | 0.610 |
Why?
| | Leukocytes, Mononuclear | 5 | 2021 | 496 | 0.610 |
Why?
| | Monocytes | 2 | 2020 | 504 | 0.600 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 14 | 0.590 |
Why?
| | Survival Rate | 17 | 2021 | 1644 | 0.580 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 7 | 0.560 |
Why?
| | Pylorus | 1 | 2017 | 11 | 0.560 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2023 | 692 | 0.560 |
Why?
| | Head and Neck Neoplasms | 5 | 2019 | 436 | 0.550 |
Why?
| | Soft Tissue Neoplasms | 3 | 2022 | 90 | 0.550 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 152 | 0.540 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 30 | 0.540 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 40 | 0.530 |
Why?
| | Leucovorin | 2 | 2019 | 43 | 0.530 |
Why?
| | Antineoplastic Agents | 8 | 2021 | 1897 | 0.510 |
Why?
| | Combined Modality Therapy | 13 | 2023 | 1126 | 0.490 |
Why?
| | Chemoradiotherapy | 5 | 2023 | 190 | 0.470 |
Why?
| | Vitamin B Complex | 1 | 2014 | 38 | 0.470 |
Why?
| | Immune Tolerance | 4 | 2016 | 328 | 0.470 |
Why?
| | Salvage Therapy | 2 | 2014 | 127 | 0.460 |
Why?
| | Treatment Outcome | 24 | 2023 | 9105 | 0.460 |
Why?
| | Lymphocytes | 3 | 2021 | 333 | 0.460 |
Why?
| | Minimally Invasive Surgical Procedures | 6 | 2023 | 153 | 0.460 |
Why?
| | Pelvis | 1 | 2014 | 90 | 0.450 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 89 | 0.440 |
Why?
| | Pancreatectomy | 4 | 2021 | 171 | 0.440 |
Why?
| | Ear, External | 1 | 2013 | 24 | 0.430 |
Why?
| | Ischemic Preconditioning | 2 | 2023 | 28 | 0.430 |
Why?
| | Mohs Surgery | 1 | 2013 | 25 | 0.430 |
Why?
| | Mutation | 8 | 2022 | 3353 | 0.420 |
Why?
| | Follow-Up Studies | 15 | 2019 | 4427 | 0.420 |
Why?
| | Palliative Care | 1 | 2019 | 640 | 0.420 |
Why?
| | Liver Neoplasms | 5 | 2016 | 509 | 0.420 |
Why?
| | T-Lymphocytes, Helper-Inducer | 4 | 2017 | 128 | 0.410 |
Why?
| | Biopsy | 3 | 2023 | 1045 | 0.410 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2014 | 584 | 0.400 |
Why?
| | Esophagogastric Junction | 3 | 2021 | 42 | 0.400 |
Why?
| | Hematologic Diseases | 1 | 2012 | 57 | 0.400 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 248 | 0.390 |
Why?
| | Suppressor Factors, Immunologic | 1 | 2011 | 4 | 0.390 |
Why?
| | Cytokines | 8 | 2021 | 1843 | 0.390 |
Why?
| | Receptors, CCR5 | 3 | 2021 | 54 | 0.390 |
Why?
| | Colonic Neoplasms | 6 | 2012 | 222 | 0.380 |
Why?
| | Prospective Studies | 19 | 2023 | 6218 | 0.380 |
Why?
| | Up-Regulation | 4 | 2012 | 812 | 0.380 |
Why?
| | Induction Chemotherapy | 2 | 2021 | 56 | 0.370 |
Why?
| | Granzymes | 2 | 2021 | 40 | 0.360 |
Why?
| | Conversion to Open Surgery | 2 | 2020 | 13 | 0.350 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2022 | 102 | 0.350 |
Why?
| | Homosexuality, Male | 3 | 2021 | 170 | 0.350 |
Why?
| | Benzamides | 5 | 2014 | 169 | 0.350 |
Why?
| | Esophageal Achalasia | 2 | 2021 | 25 | 0.340 |
Why?
| | Young Adult | 18 | 2019 | 10478 | 0.340 |
Why?
| | Retroperitoneal Neoplasms | 3 | 2021 | 22 | 0.340 |
Why?
| | Medical Oncology | 4 | 2022 | 228 | 0.340 |
Why?
| | Mucous Membrane | 4 | 2023 | 108 | 0.330 |
Why?
| | Interferon-gamma | 6 | 2019 | 723 | 0.330 |
Why?
| | Wounds and Injuries | 4 | 2009 | 723 | 0.330 |
Why?
| | Membrane Glycoproteins | 3 | 2015 | 429 | 0.320 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 10 | 0.320 |
Why?
| | Cell Differentiation | 5 | 2016 | 1699 | 0.320 |
Why?
| | Butyrates | 2 | 2021 | 53 | 0.320 |
Why?
| | Barrett Esophagus | 3 | 2020 | 147 | 0.320 |
Why?
| | Interleukin-15 | 2 | 2021 | 75 | 0.310 |
Why?
| | Killer Cells, Natural | 2 | 2023 | 384 | 0.310 |
Why?
| | Immunity, Mucosal | 3 | 2016 | 84 | 0.310 |
Why?
| | Blood Preservation | 2 | 2009 | 263 | 0.310 |
Why?
| | Chemotherapy, Adjuvant | 9 | 2023 | 333 | 0.310 |
Why?
| | Disease-Free Survival | 8 | 2019 | 623 | 0.300 |
Why?
| | Inflammation Mediators | 2 | 2018 | 476 | 0.300 |
Why?
| | Colon | 3 | 2021 | 233 | 0.290 |
Why?
| | Prostatic Neoplasms | 1 | 2014 | 925 | 0.290 |
Why?
| | Nomograms | 2 | 2019 | 41 | 0.290 |
Why?
| | Dysbiosis | 3 | 2021 | 146 | 0.280 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 12 | 0.280 |
Why?
| | Immunocompromised Host | 1 | 2008 | 196 | 0.280 |
Why?
| | Erythrocyte Transfusion | 1 | 2008 | 186 | 0.280 |
Why?
| | Cells, Cultured | 9 | 2021 | 3897 | 0.270 |
Why?
| | Population Surveillance | 2 | 2021 | 392 | 0.270 |
Why?
| | Splenic Neoplasms | 1 | 2006 | 2 | 0.270 |
Why?
| | Forkhead Transcription Factors | 1 | 2007 | 171 | 0.270 |
Why?
| | Lymphangioma | 1 | 2006 | 7 | 0.270 |
Why?
| | Th2 Cells | 2 | 2005 | 154 | 0.270 |
Why?
| | Pelvic Neoplasms | 3 | 2012 | 18 | 0.270 |
Why?
| | General Surgery | 1 | 2007 | 126 | 0.260 |
Why?
| | Receptors, Cell Surface | 2 | 2021 | 354 | 0.260 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 212 | 0.260 |
Why?
| | Immunity, Innate | 4 | 2021 | 724 | 0.260 |
Why?
| | Transplantation Immunology | 1 | 2005 | 30 | 0.260 |
Why?
| | Mentors | 1 | 2007 | 158 | 0.260 |
Why?
| | Neuroendocrine Tumors | 2 | 2017 | 85 | 0.260 |
Why?
| | Catheter Ablation | 4 | 2016 | 291 | 0.260 |
Why?
| | Macrophages, Peritoneal | 3 | 2005 | 91 | 0.260 |
Why?
| | Exome | 2 | 2017 | 201 | 0.250 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 1 | 2005 | 7 | 0.250 |
Why?
| | B-Lymphocytes | 3 | 2017 | 772 | 0.250 |
Why?
| | Virus Replication | 5 | 2017 | 393 | 0.250 |
Why?
| | Microbiota | 3 | 2024 | 649 | 0.250 |
Why?
| | Interleukin-10 | 3 | 2016 | 296 | 0.240 |
Why?
| | Radiation Injuries | 2 | 2021 | 128 | 0.240 |
Why?
| | Signal Transduction | 9 | 2023 | 4524 | 0.240 |
Why?
| | Culture Media, Conditioned | 4 | 2011 | 105 | 0.240 |
Why?
| | Adolescent | 15 | 2019 | 17829 | 0.240 |
Why?
| | Nevus, Pigmented | 1 | 2005 | 34 | 0.240 |
Why?
| | Th1 Cells | 2 | 2019 | 123 | 0.240 |
Why?
| | Macrophage Activation | 1 | 2005 | 164 | 0.240 |
Why?
| | Erythrocytes | 1 | 2009 | 591 | 0.230 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 114 | 0.230 |
Why?
| | Feces | 4 | 2021 | 374 | 0.230 |
Why?
| | Anus Neoplasms | 2 | 2003 | 24 | 0.230 |
Why?
| | Lymphangiogenesis | 1 | 2004 | 24 | 0.230 |
Why?
| | Lymphocyte Count | 5 | 2017 | 133 | 0.230 |
Why?
| | Flow Cytometry | 6 | 2017 | 1087 | 0.230 |
Why?
| | Interferon-alpha | 3 | 2015 | 187 | 0.230 |
Why?
| | Ruminococcus | 2 | 2021 | 9 | 0.220 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 374 | 0.220 |
Why?
| | Enterobacteriaceae | 2 | 2017 | 32 | 0.220 |
Why?
| | In Vitro Techniques | 5 | 2019 | 1034 | 0.220 |
Why?
| | Paget Disease, Extramammary | 1 | 2003 | 3 | 0.220 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 192 | 0.220 |
Why?
| | Lymphoid Tissue | 3 | 2008 | 62 | 0.210 |
Why?
| | Neoplasm Metastasis | 2 | 2007 | 530 | 0.210 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 9 | 0.210 |
Why?
| | Lysophospholipids | 1 | 2023 | 65 | 0.210 |
Why?
| | Specialties, Surgical | 1 | 2023 | 70 | 0.210 |
Why?
| | Transforming Growth Factor beta | 4 | 2015 | 449 | 0.210 |
Why?
| | Tomography, X-Ray Computed | 6 | 2016 | 2326 | 0.210 |
Why?
| | Biomarkers, Tumor | 4 | 2017 | 1054 | 0.210 |
Why?
| | Intestines | 2 | 2017 | 326 | 0.210 |
Why?
| | Protein-Energy Malnutrition | 2 | 2003 | 6 | 0.210 |
Why?
| | Salmonella typhimurium | 2 | 2021 | 158 | 0.210 |
Why?
| | Time Factors | 9 | 2014 | 6125 | 0.210 |
Why?
| | Hepatectomy | 2 | 2016 | 119 | 0.210 |
Why?
| | Cell Count | 2 | 2017 | 305 | 0.200 |
Why?
| | Mice | 20 | 2022 | 14935 | 0.200 |
Why?
| | Bacteria | 3 | 2018 | 728 | 0.200 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 136 | 0.200 |
Why?
| | Tumor Microenvironment | 5 | 2024 | 434 | 0.200 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 15 | 0.200 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 21 | 0.200 |
Why?
| | Disease Progression | 2 | 2022 | 2392 | 0.200 |
Why?
| | Imatinib Mesylate | 5 | 2014 | 63 | 0.200 |
Why?
| | HIV Seropositivity | 1 | 2022 | 109 | 0.200 |
Why?
| | Cryosurgery | 2 | 2019 | 52 | 0.200 |
Why?
| | Critical Pathways | 1 | 2022 | 74 | 0.200 |
Why?
| | Esophagoscopy | 2 | 2020 | 184 | 0.200 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 34 | 0.200 |
Why?
| | Acinetobacter | 1 | 2021 | 13 | 0.190 |
Why?
| | Glucose | 3 | 2020 | 897 | 0.190 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2022 | 155 | 0.190 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 142 | 0.190 |
Why?
| | Seminoma | 1 | 2021 | 17 | 0.190 |
Why?
| | ADAM10 Protein | 1 | 2021 | 28 | 0.190 |
Why?
| | Firmicutes | 1 | 2021 | 17 | 0.180 |
Why?
| | Anastomosis, Surgical | 2 | 2023 | 136 | 0.180 |
Why?
| | Gamma Rays | 1 | 2021 | 48 | 0.180 |
Why?
| | Interleukin-2 | 5 | 2022 | 419 | 0.180 |
Why?
| | Delivery of Health Care | 2 | 2021 | 834 | 0.180 |
Why?
| | Bacterial Translocation | 2 | 2019 | 36 | 0.180 |
Why?
| | Diarrhea | 3 | 2008 | 173 | 0.180 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 73 | 0.180 |
Why?
| | Group II Phospholipases A2 | 1 | 2020 | 19 | 0.180 |
Why?
| | Receptors, CCR | 1 | 2020 | 7 | 0.180 |
Why?
| | Carcinoembryonic Antigen | 2 | 2022 | 37 | 0.180 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 62 | 0.170 |
Why?
| | Cell Proliferation | 6 | 2021 | 2199 | 0.170 |
Why?
| | Interleukins | 2 | 2019 | 236 | 0.170 |
Why?
| | Platelet Count | 1 | 2020 | 81 | 0.170 |
Why?
| | Risk Factors | 11 | 2019 | 8637 | 0.170 |
Why?
| | Decision Making | 2 | 2019 | 781 | 0.170 |
Why?
| | Surgeons | 1 | 2023 | 237 | 0.170 |
Why?
| | Basophils | 1 | 2020 | 64 | 0.170 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 198 | 0.170 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 79 | 0.170 |
Why?
| | Patient Care Planning | 2 | 2016 | 139 | 0.170 |
Why?
| | Gastric Bypass | 1 | 2021 | 92 | 0.170 |
Why?
| | Scalp | 1 | 2019 | 29 | 0.170 |
Why?
| | Dacarbazine | 4 | 2012 | 101 | 0.170 |
Why?
| | Apoptosis | 5 | 2021 | 2371 | 0.170 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 168 | 0.170 |
Why?
| | Immunophenotyping | 2 | 2017 | 277 | 0.170 |
Why?
| | Th17 Cells | 1 | 2019 | 59 | 0.170 |
Why?
| | Sclerosing Solutions | 1 | 2019 | 9 | 0.160 |
Why?
| | Argon Plasma Coagulation | 1 | 2019 | 4 | 0.160 |
Why?
| | Leukocyte Count | 1 | 2020 | 292 | 0.160 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2022 | 40 | 0.160 |
Why?
| | Germ-Free Life | 1 | 2019 | 29 | 0.160 |
Why?
| | Preoperative Care | 2 | 2018 | 317 | 0.160 |
Why?
| | Sclerotherapy | 1 | 2019 | 19 | 0.160 |
Why?
| | CD4 Antigens | 2 | 2011 | 124 | 0.160 |
Why?
| | Haploinsufficiency | 1 | 2019 | 44 | 0.160 |
Why?
| | Animals | 23 | 2022 | 31837 | 0.160 |
Why?
| | Nutritional Support | 1 | 2019 | 27 | 0.160 |
Why?
| | Immunotherapy | 4 | 2024 | 475 | 0.160 |
Why?
| | Survivors | 2 | 2015 | 411 | 0.160 |
Why?
| | Self Expandable Metallic Stents | 1 | 2019 | 14 | 0.160 |
Why?
| | Abdominal Neoplasms | 2 | 2010 | 26 | 0.160 |
Why?
| | Tissue and Organ Procurement | 1 | 2022 | 228 | 0.160 |
Why?
| | Mastocytosis | 1 | 2019 | 12 | 0.160 |
Why?
| | Photochemotherapy | 1 | 2019 | 29 | 0.160 |
Why?
| | Intestinal Perforation | 1 | 2019 | 38 | 0.160 |
Why?
| | Postoperative Period | 1 | 2020 | 289 | 0.160 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 79 | 0.160 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 45 | 0.160 |
Why?
| | HLA-DR Antigens | 2 | 2011 | 220 | 0.160 |
Why?
| | Intestinal Obstruction | 1 | 2019 | 40 | 0.160 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 66 | 0.160 |
Why?
| | Skin Pigmentation | 1 | 2019 | 39 | 0.160 |
Why?
| | Dilatation | 1 | 2019 | 60 | 0.160 |
Why?
| | Environmental Restoration and Remediation | 1 | 2018 | 8 | 0.160 |
Why?
| | Esophagus | 1 | 2020 | 226 | 0.160 |
Why?
| | Fibrosis | 1 | 2021 | 454 | 0.160 |
Why?
| | Hospitals | 2 | 2021 | 581 | 0.150 |
Why?
| | Brachytherapy | 1 | 2019 | 104 | 0.150 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 131 | 0.150 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 231 | 0.150 |
Why?
| | Liver | 4 | 2016 | 1634 | 0.150 |
Why?
| | Septins | 1 | 2018 | 40 | 0.150 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2018 | 22 | 0.150 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 4 | 0.150 |
Why?
| | Laser Therapy | 1 | 2019 | 100 | 0.150 |
Why?
| | Cell Movement | 4 | 2022 | 867 | 0.150 |
Why?
| | HIV | 1 | 2019 | 208 | 0.150 |
Why?
| | Enteral Nutrition | 2 | 2010 | 157 | 0.150 |
Why?
| | Down-Regulation | 1 | 2020 | 596 | 0.150 |
Why?
| | Dasatinib | 1 | 2017 | 46 | 0.150 |
Why?
| | Deglutition Disorders | 1 | 2019 | 120 | 0.150 |
Why?
| | Viral Tropism | 1 | 2017 | 24 | 0.150 |
Why?
| | Food, Formulated | 1 | 1997 | 14 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 3 | 2018 | 796 | 0.140 |
Why?
| | Carcinoid Tumor | 1 | 2017 | 25 | 0.140 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 22 | 0.140 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2017 | 24 | 0.140 |
Why?
| | Ampulla of Vater | 1 | 2017 | 30 | 0.140 |
Why?
| | Fatty Acids, Omega-3 | 1 | 1998 | 122 | 0.140 |
Why?
| | src-Family Kinases | 1 | 2017 | 88 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 563 | 0.140 |
Why?
| | Arginine | 1 | 1998 | 237 | 0.140 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2019 | 204 | 0.140 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 49 | 0.140 |
Why?
| | Gastric Emptying | 1 | 2017 | 40 | 0.140 |
Why?
| | Thrombelastography | 1 | 2018 | 175 | 0.140 |
Why?
| | Perioperative Care | 1 | 2018 | 126 | 0.140 |
Why?
| | Nutritional Status | 1 | 2019 | 286 | 0.140 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 752 | 0.140 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 179 | 0.140 |
Why?
| | Gastrectomy | 1 | 2017 | 82 | 0.140 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 39 | 0.140 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 193 | 0.140 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 31 | 0.140 |
Why?
| | Immunologic Memory | 2 | 2016 | 313 | 0.140 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 8 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2002 | 1215 | 0.140 |
Why?
| | Mortality | 1 | 2018 | 288 | 0.140 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 70 | 0.140 |
Why?
| | Digestive System Surgical Procedures | 1 | 1997 | 90 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2017 | 189 | 0.130 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 17 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2018 | 244 | 0.130 |
Why?
| | Polysaccharides, Bacterial | 1 | 2016 | 66 | 0.130 |
Why?
| | Bystander Effect | 1 | 2016 | 15 | 0.130 |
Why?
| | Lymphocyte Depletion | 3 | 2013 | 116 | 0.130 |
Why?
| | Exons | 3 | 2019 | 302 | 0.130 |
Why?
| | Germinal Center | 1 | 2016 | 49 | 0.130 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 25 | 0.130 |
Why?
| | United States | 11 | 2023 | 12211 | 0.130 |
Why?
| | T-Lymphocyte Subsets | 2 | 2024 | 384 | 0.130 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 77 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 213 | 0.130 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2015 | 44 | 0.130 |
Why?
| | Morbidity | 3 | 2023 | 277 | 0.130 |
Why?
| | Postoperative Care | 1 | 1997 | 220 | 0.130 |
Why?
| | Adenoma | 1 | 2017 | 189 | 0.130 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 13 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 797 | 0.130 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 14 | 0.130 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 706 | 0.120 |
Why?
| | Quality of Life | 2 | 2019 | 2359 | 0.120 |
Why?
| | Phosphoproteins | 1 | 2017 | 299 | 0.120 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 68 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1134 | 0.120 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 213 | 0.120 |
Why?
| | Viral Load | 5 | 2018 | 405 | 0.120 |
Why?
| | Ileus | 1 | 2014 | 10 | 0.120 |
Why?
| | Receptors, Ghrelin | 1 | 2014 | 7 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2021 | 1022 | 0.120 |
Why?
| | Risk Assessment | 3 | 2019 | 2975 | 0.120 |
Why?
| | Ethanol | 1 | 2019 | 548 | 0.120 |
Why?
| | Vinblastine | 2 | 2012 | 62 | 0.120 |
Why?
| | Dietary Supplements | 1 | 1998 | 458 | 0.120 |
Why?
| | Endosonography | 1 | 2016 | 140 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2016 | 642 | 0.120 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 855 | 0.120 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 60 | 0.120 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2223 | 0.110 |
Why?
| | Pilot Projects | 1 | 2018 | 1372 | 0.110 |
Why?
| | Fluorouracil | 2 | 2019 | 152 | 0.110 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 169 | 0.110 |
Why?
| | Tumor Burden | 4 | 2022 | 262 | 0.110 |
Why?
| | Blood Cell Count | 1 | 2013 | 52 | 0.110 |
Why?
| | RNA, Viral | 3 | 2013 | 565 | 0.110 |
Why?
| | Registries | 1 | 2021 | 1760 | 0.110 |
Why?
| | Colectomy | 3 | 2008 | 86 | 0.110 |
Why?
| | Databases, Factual | 4 | 2019 | 1125 | 0.110 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 82 | 0.110 |
Why?
| | Cisplatin | 2 | 2012 | 263 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 451 | 0.110 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2013 | 60 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2102 | 0.110 |
Why?
| | Stomach | 2 | 2023 | 101 | 0.110 |
Why?
| | Oligopeptides | 1 | 2014 | 235 | 0.110 |
Why?
| | HIV Antibodies | 1 | 2013 | 49 | 0.100 |
Why?
| | Biomarkers | 2 | 2020 | 3418 | 0.100 |
Why?
| | Hospital Mortality | 2 | 2016 | 776 | 0.100 |
Why?
| | Side-Population Cells | 1 | 2012 | 9 | 0.100 |
Why?
| | Ablation Techniques | 1 | 2012 | 29 | 0.100 |
Why?
| | Chi-Square Distribution | 3 | 2014 | 495 | 0.100 |
Why?
| | Palatine Tonsil | 3 | 2017 | 32 | 0.100 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 126 | 0.100 |
Why?
| | Biological Therapy | 1 | 2012 | 27 | 0.100 |
Why?
| | Macrophages | 2 | 2001 | 1266 | 0.100 |
Why?
| | Elective Surgical Procedures | 1 | 2013 | 151 | 0.100 |
Why?
| | Efficiency, Organizational | 1 | 2013 | 126 | 0.100 |
Why?
| | Patient Care Team | 1 | 2016 | 516 | 0.100 |
Why?
| | Escherichia coli Infections | 1 | 2012 | 100 | 0.100 |
Why?
| | Time-to-Treatment | 1 | 2013 | 147 | 0.100 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2019 | 486 | 0.100 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2011 | 35 | 0.100 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2012 | 134 | 0.100 |
Why?
| | Predictive Value of Tests | 5 | 2018 | 1801 | 0.100 |
Why?
| | Proctocolectomy, Restorative | 1 | 2011 | 19 | 0.100 |
Why?
| | Colonic Pouches | 1 | 2011 | 14 | 0.090 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 166 | 0.090 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 4718 | 0.090 |
Why?
| | Intestinal Neoplasms | 1 | 2011 | 24 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2016 | 634 | 0.090 |
Why?
| | Ligands | 2 | 2023 | 565 | 0.090 |
Why?
| | Antibodies, Neutralizing | 1 | 2013 | 221 | 0.090 |
Why?
| | Antigens, Neoplasm | 2 | 2009 | 222 | 0.090 |
Why?
| | Extremities | 2 | 2022 | 113 | 0.090 |
Why?
| | Multivariate Analysis | 4 | 2016 | 1440 | 0.090 |
Why?
| | Antigens, CD | 2 | 2015 | 443 | 0.090 |
Why?
| | Endocytosis | 1 | 2011 | 151 | 0.090 |
Why?
| | Cell Separation | 2 | 2010 | 292 | 0.090 |
Why?
| | Toll-Like Receptor 8 | 1 | 2010 | 5 | 0.090 |
Why?
| | Heparin | 1 | 2012 | 222 | 0.090 |
Why?
| | Cohort Studies | 5 | 2019 | 4903 | 0.090 |
Why?
| | Interleukin-23 | 1 | 2010 | 15 | 0.090 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 312 | 0.090 |
Why?
| | Vascular Surgical Procedures | 1 | 2013 | 257 | 0.090 |
Why?
| | Gastric Fistula | 1 | 2010 | 4 | 0.090 |
Why?
| | Toll-Like Receptor 7 | 1 | 2010 | 35 | 0.090 |
Why?
| | Escherichia coli | 1 | 2014 | 722 | 0.090 |
Why?
| | Double-Blind Method | 4 | 2014 | 1663 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2015 | 647 | 0.090 |
Why?
| | Cutaneous Fistula | 1 | 2010 | 13 | 0.090 |
Why?
| | Colitis, Ulcerative | 1 | 2011 | 105 | 0.090 |
Why?
| | Viremia | 1 | 2010 | 123 | 0.090 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1355 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 238 | 0.080 |
Why?
| | Phenotype | 5 | 2019 | 2817 | 0.080 |
Why?
| | Odds Ratio | 3 | 2019 | 954 | 0.080 |
Why?
| | Immunoglobulins | 2 | 2023 | 143 | 0.080 |
Why?
| | Cell Transplantation | 1 | 2009 | 37 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 975 | 0.080 |
Why?
| | Gastrostomy | 1 | 2010 | 89 | 0.080 |
Why?
| | Paracrine Communication | 1 | 2009 | 56 | 0.080 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 334 | 0.080 |
Why?
| | Radiotherapy, Conformal | 1 | 2009 | 68 | 0.080 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2024 | 620 | 0.080 |
Why?
| | Age Factors | 3 | 2019 | 2891 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2022 | 1148 | 0.080 |
Why?
| | Hyalin | 1 | 2008 | 5 | 0.080 |
Why?
| | Prosthesis Implantation | 1 | 2010 | 139 | 0.080 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2008 | 25 | 0.080 |
Why?
| | Dermatofibrosarcoma | 1 | 2008 | 9 | 0.080 |
Why?
| | ras Proteins | 1 | 2009 | 138 | 0.080 |
Why?
| | Length of Stay | 3 | 2019 | 949 | 0.080 |
Why?
| | Chemokine CXCL12 | 1 | 2008 | 74 | 0.080 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2008 | 59 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 817 | 0.080 |
Why?
| | Interleukin-4 | 2 | 2007 | 208 | 0.080 |
Why?
| | DNA Mutational Analysis | 3 | 2016 | 372 | 0.080 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2008 | 129 | 0.080 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2023 | 195 | 0.080 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2024 | 441 | 0.070 |
Why?
| | Logistic Models | 4 | 2016 | 1844 | 0.070 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 488 | 0.070 |
Why?
| | Critical Care | 1 | 2012 | 474 | 0.070 |
Why?
| | Anticoagulants | 1 | 2012 | 547 | 0.070 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2007 | 17 | 0.070 |
Why?
| | Deoxycytidine | 1 | 2008 | 138 | 0.070 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 66 | 0.070 |
Why?
| | Interleukin-6 | 4 | 1999 | 676 | 0.070 |
Why?
| | Phylogeny | 2 | 2024 | 795 | 0.070 |
Why?
| | Career Mobility | 1 | 2007 | 63 | 0.070 |
Why?
| | Mice, Knockout | 3 | 2022 | 2586 | 0.070 |
Why?
| | Interleukin-1beta | 2 | 2019 | 370 | 0.070 |
Why?
| | Watchful Waiting | 2 | 2018 | 56 | 0.070 |
Why?
| | DNA, Bacterial | 2 | 2019 | 310 | 0.070 |
Why?
| | Blood Transfusion | 1 | 2009 | 276 | 0.070 |
Why?
| | alpha-Defensins | 1 | 2006 | 11 | 0.070 |
Why?
| | Computational Biology | 2 | 2024 | 531 | 0.070 |
Why?
| | History, 20th Century | 1 | 2007 | 267 | 0.070 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 12 | 0.070 |
Why?
| | Laparotomy | 1 | 2007 | 96 | 0.070 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1635 | 0.070 |
Why?
| | Intestine, Small | 1 | 2007 | 122 | 0.070 |
Why?
| | Collagen | 1 | 2008 | 416 | 0.070 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 817 | 0.060 |
Why?
| | Interleukin-17 | 2 | 2019 | 104 | 0.060 |
Why?
| | Mice, Inbred BALB C | 5 | 2003 | 1152 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2005 | 42 | 0.060 |
Why?
| | Obesity, Morbid | 1 | 2008 | 197 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2007 | 249 | 0.060 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 2725 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2009 | 611 | 0.060 |
Why?
| | Cell Division | 2 | 2005 | 759 | 0.060 |
Why?
| | Culture Media | 1 | 2005 | 155 | 0.060 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 52 | 0.060 |
Why?
| | Thoracic Neoplasms | 1 | 2005 | 33 | 0.060 |
Why?
| | Quality Improvement | 1 | 2012 | 954 | 0.060 |
Why?
| | Faculty, Medical | 1 | 2007 | 232 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2005 | 2558 | 0.060 |
Why?
| | Mice, Inbred Strains | 1 | 2005 | 398 | 0.060 |
Why?
| | Fellowships and Scholarships | 1 | 2007 | 227 | 0.060 |
Why?
| | Nitric Oxide | 2 | 2001 | 827 | 0.060 |
Why?
| | Leadership | 1 | 2007 | 295 | 0.060 |
Why?
| | Surgical Procedures, Operative | 1 | 2006 | 206 | 0.060 |
Why?
| | Carcinoma | 1 | 2006 | 199 | 0.060 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 51 | 0.060 |
Why?
| | New York | 1 | 2023 | 106 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 445 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 23 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 29 | 0.050 |
Why?
| | Child | 4 | 2019 | 18366 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 12 | 0.050 |
Why?
| | Toll-Like Receptor 4 | 1 | 2005 | 286 | 0.050 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2023 | 40 | 0.050 |
Why?
| | Antigens, CD1 | 2 | 2015 | 57 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 92 | 0.050 |
Why?
| | Body Weight | 4 | 2003 | 868 | 0.050 |
Why?
| | Axilla | 2 | 2017 | 39 | 0.050 |
Why?
| | Hypoglycemia | 1 | 2007 | 386 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 296 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 8 | 0.050 |
Why?
| | Veterans | 1 | 2013 | 1240 | 0.050 |
Why?
| | Corticosterone | 1 | 2003 | 211 | 0.050 |
Why?
| | Dietary Proteins | 1 | 2003 | 123 | 0.050 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 56 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 309 | 0.050 |
Why?
| | NF-kappa B | 1 | 2005 | 637 | 0.050 |
Why?
| | Leptin | 1 | 2003 | 211 | 0.050 |
Why?
| | Precision Medicine | 2 | 2016 | 339 | 0.050 |
Why?
| | Propionates | 1 | 2021 | 34 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 243 | 0.050 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 37 | 0.050 |
Why?
| | Mediastinoscopy | 1 | 2021 | 3 | 0.050 |
Why?
| | Body Mass Index | 1 | 2008 | 1961 | 0.050 |
Why?
| | Glycoproteins | 2 | 2015 | 305 | 0.050 |
Why?
| | Positron-Emission Tomography | 3 | 2008 | 265 | 0.050 |
Why?
| | Ephrin-B2 | 1 | 2021 | 36 | 0.050 |
Why?
| | Neoplasm Transplantation | 3 | 2012 | 232 | 0.050 |
Why?
| | Acetates | 1 | 2021 | 95 | 0.050 |
Why?
| | Cholangiography | 1 | 2000 | 16 | 0.050 |
Why?
| | Acetylation | 1 | 2021 | 211 | 0.050 |
Why?
| | Fibroblasts | 1 | 2005 | 839 | 0.050 |
Why?
| | Thoracoscopy | 1 | 2020 | 53 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 184 | 0.040 |
Why?
| | Tissue Banks | 1 | 2020 | 18 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 387 | 0.040 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 17 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 106 | 0.040 |
Why?
| | Regression Analysis | 2 | 2019 | 947 | 0.040 |
Why?
| | Coloring Agents | 2 | 2012 | 72 | 0.040 |
Why?
| | Interleukin-12 Subunit p35 | 1 | 2019 | 3 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 517 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 33 | 0.040 |
Why?
| | Eating | 2 | 2003 | 347 | 0.040 |
Why?
| | Margins of Excision | 1 | 2019 | 29 | 0.040 |
Why?
| | Paclitaxel | 2 | 2012 | 190 | 0.040 |
Why?
| | Radiography | 2 | 2016 | 819 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2012 | 1227 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2017 | 3008 | 0.040 |
Why?
| | Tight Junctions | 1 | 2019 | 68 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 435 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2022 | 583 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 103 | 0.040 |
Why?
| | Montana | 1 | 2018 | 16 | 0.040 |
Why?
| | United States Environmental Protection Agency | 1 | 2018 | 23 | 0.040 |
Why?
| | Mitogens | 1 | 1998 | 58 | 0.040 |
Why?
| | Keratins | 2 | 2010 | 176 | 0.040 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 138 | 0.040 |
Why?
| | Cachexia | 1 | 1999 | 52 | 0.040 |
Why?
| | Interleukin-18 | 1 | 2019 | 219 | 0.040 |
Why?
| | Robotic Surgical Procedures | 1 | 2019 | 86 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 447 | 0.040 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 111 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2020 | 301 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1700 | 0.040 |
Why?
| | Qualitative Research | 1 | 2022 | 936 | 0.040 |
Why?
| | Pedigree | 1 | 2019 | 467 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2002 | 675 | 0.040 |
Why?
| | Perioperative Period | 1 | 2017 | 49 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2018 | 176 | 0.040 |
Why?
| | Jejunostomy | 1 | 1997 | 11 | 0.040 |
Why?
| | Femoral Fractures | 1 | 1998 | 67 | 0.040 |
Why?
| | Rosaniline Dyes | 2 | 2007 | 10 | 0.040 |
Why?
| | Dinoprostone | 1 | 1998 | 184 | 0.040 |
Why?
| | Operative Time | 1 | 2017 | 106 | 0.040 |
Why?
| | Candidiasis | 1 | 1997 | 52 | 0.040 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 106 | 0.040 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 153 | 0.040 |
Why?
| | Parotid Gland | 1 | 2017 | 25 | 0.040 |
Why?
| | Occipital Bone | 1 | 2017 | 18 | 0.040 |
Why?
| | Liver Circulation | 1 | 2016 | 19 | 0.040 |
Why?
| | Infection Control | 1 | 1998 | 135 | 0.040 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 80 | 0.040 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2016 | 33 | 0.030 |
Why?
| | Quality of Health Care | 2 | 2012 | 573 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 561 | 0.030 |
Why?
| | Radiotherapy Dosage | 2 | 2008 | 245 | 0.030 |
Why?
| | Histones | 1 | 2021 | 536 | 0.030 |
Why?
| | Neck | 1 | 2017 | 83 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 369 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 195 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 1897 | 0.030 |
Why?
| | Models, Anatomic | 1 | 2016 | 87 | 0.030 |
Why?
| | Superinfection | 1 | 2016 | 5 | 0.030 |
Why?
| | Hydrogen Peroxide | 1 | 1998 | 287 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 390 | 0.030 |
Why?
| | Receptors, CXCR5 | 1 | 2016 | 11 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2008 | 182 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2010 | 737 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2017 | 4407 | 0.030 |
Why?
| | Host Specificity | 1 | 2016 | 22 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 929 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 392 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 77 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2016 | 149 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1325 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 75 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 460 | 0.030 |
Why?
| | Prevotella | 1 | 2015 | 12 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2015 | 131 | 0.030 |
Why?
| | Virion | 1 | 2015 | 73 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 591 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 159 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 110 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2019 | 440 | 0.030 |
Why?
| | Cell Cycle | 1 | 2017 | 544 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2008 | 3053 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1998 | 399 | 0.030 |
Why?
| | CD40 Antigens | 1 | 2015 | 82 | 0.030 |
Why?
| | Glucocorticoids | 1 | 1999 | 534 | 0.030 |
Why?
| | Nausea | 1 | 2014 | 104 | 0.030 |
Why?
| | Patient Readmission | 1 | 2019 | 608 | 0.030 |
Why?
| | Mitotic Index | 1 | 2014 | 26 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 729 | 0.030 |
Why?
| | Cattle | 1 | 2016 | 924 | 0.030 |
Why?
| | Vomiting | 1 | 2014 | 124 | 0.030 |
Why?
| | Colitis | 1 | 2016 | 226 | 0.030 |
Why?
| | Inflammation | 2 | 2019 | 2485 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 448 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 269 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2770 | 0.030 |
Why?
| | Phosphorylation | 1 | 1998 | 1572 | 0.030 |
Why?
| | Hemorrhage | 1 | 1998 | 618 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 257 | 0.030 |
Why?
| | Caspase 1 | 1 | 2014 | 140 | 0.030 |
Why?
| | Cell Lineage | 1 | 2015 | 310 | 0.030 |
Why?
| | Autoantigens | 1 | 2016 | 397 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 10 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1400 | 0.030 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 42 | 0.030 |
Why?
| | Clinical Competence | 1 | 2019 | 901 | 0.030 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2013 | 72 | 0.030 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2013 | 56 | 0.030 |
Why?
| | AIDS Vaccines | 1 | 2013 | 41 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 41 | 0.030 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 31 | 0.030 |
Why?
| | International Agencies | 1 | 2012 | 29 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2013 | 176 | 0.030 |
Why?
| | Thoracotomy | 1 | 2012 | 68 | 0.030 |
Why?
| | Homeostasis | 1 | 2016 | 576 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2013 | 198 | 0.030 |
Why?
| | Response Elements | 1 | 2012 | 83 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2013 | 243 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2013 | 353 | 0.030 |
Why?
| | Calcium | 1 | 1998 | 1104 | 0.020 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2013 | 113 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 309 | 0.020 |
Why?
| | APACHE | 1 | 2012 | 58 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 172 | 0.020 |
Why?
| | Blood Coagulation Tests | 1 | 2012 | 57 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 320 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 23 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 285 | 0.020 |
Why?
| | Transcriptome | 1 | 2017 | 728 | 0.020 |
Why?
| | Species Specificity | 1 | 2013 | 547 | 0.020 |
Why?
| | Bone Marrow | 1 | 2013 | 245 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 718 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 280 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 238 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2012 | 258 | 0.020 |
Why?
| | Models, Animal | 1 | 2013 | 346 | 0.020 |
Why?
| | CA-19-9 Antigen | 1 | 2010 | 14 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1422 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1080 | 0.020 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 20 | 0.020 |
Why?
| | Factor Xa Inhibitors | 1 | 2012 | 138 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 561 | 0.020 |
Why?
| | Risk | 1 | 2013 | 815 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 1022 | 0.020 |
Why?
| | Universities | 1 | 2013 | 339 | 0.020 |
Why?
| | Mice, Nude | 1 | 2012 | 635 | 0.020 |
Why?
| | Incidence | 1 | 1996 | 2316 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1523 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 543 | 0.020 |
Why?
| | Patient Selection | 1 | 2014 | 642 | 0.020 |
Why?
| | Gastroscopy | 1 | 2010 | 18 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 134 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1593 | 0.020 |
Why?
| | Renal Dialysis | 1 | 2013 | 369 | 0.020 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2009 | 65 | 0.020 |
Why?
| | Keratin-20 | 1 | 2008 | 1 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2008 | 6 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 11 | 0.020 |
Why?
| | Chloroquine | 1 | 2009 | 52 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2013 | 776 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 1988 | 0.020 |
Why?
| | Liver Regeneration | 1 | 2008 | 29 | 0.020 |
Why?
| | Device Removal | 1 | 2010 | 127 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2008 | 128 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 140 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 159 | 0.020 |
Why?
| | Chemokine CX3CL1 | 1 | 2008 | 21 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 36 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 45 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1721 | 0.020 |
Why?
| | Program Evaluation | 1 | 2012 | 824 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2008 | 69 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2008 | 89 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 229 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2791 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1379 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 82 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 1953 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 233 | 0.020 |
Why?
| | Acute Disease | 2 | 2003 | 915 | 0.020 |
Why?
| | Swine | 1 | 2010 | 701 | 0.020 |
Why?
| | Quinazolines | 1 | 2009 | 243 | 0.020 |
Why?
| | Body Composition | 2 | 2003 | 585 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 3549 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 514 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2007 | 196 | 0.020 |
Why?
| | Lewis X Antigen | 1 | 2006 | 4 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 225 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 995 | 0.020 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 170 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2324 | 0.020 |
Why?
| | Whole Body Imaging | 1 | 2006 | 21 | 0.020 |
Why?
| | Infant | 1 | 2019 | 7937 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2007 | 300 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2008 | 385 | 0.020 |
Why?
| | Patient Discharge | 1 | 2011 | 769 | 0.020 |
Why?
| | Radiotherapy | 1 | 2006 | 176 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2006 | 398 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2118 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 78 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4091 | 0.010 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2003 | 59 | 0.010 |
Why?
| | Adrenalectomy | 1 | 2003 | 60 | 0.010 |
Why?
| | Appetite Regulation | 1 | 2003 | 26 | 0.010 |
Why?
| | Drug Implants | 1 | 2003 | 70 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 335 | 0.010 |
Why?
| | Cycloheximide | 1 | 2001 | 54 | 0.010 |
Why?
| | Dactinomycin | 1 | 2001 | 25 | 0.010 |
Why?
| | Peritoneum | 1 | 2001 | 36 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 242 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2001 | 201 | 0.010 |
Why?
| | Mifepristone | 1 | 1999 | 60 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 1999 | 33 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 1999 | 173 | 0.010 |
Why?
| | Candida albicans | 1 | 1997 | 51 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 1856 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 2514 | 0.010 |
Why?
| | RNA | 1 | 2001 | 810 | 0.010 |
Why?
| | Injury Severity Score | 1 | 1996 | 457 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 5527 | 0.010 |
Why?
| | Kidney | 1 | 1997 | 1184 | 0.010 |
Why?
|
|
McCarter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|